We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
-13.19%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.35B
AUM Growth
-$406M
Cap. Flow
+$12.3M
Cap. Flow %
0.52%
Top 10 Hldgs %
43.47%
Holding
145
New
11
Increased
25
Reduced
9
Closed
5

Top Buys

Rank Stock Value
1
MDT icon
Medtronic
MDT
+$32.6M
2
LLY icon
Eli Lilly
LLY
+$25.1M
3
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$22.3M
4
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$15.3M
5
WELL.PRI
Welltower Inc.
WELL.PRI
+$11.7M

Top Sells

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$58.6M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$38.9M
3
ILMN icon
Illumina
ILMN
+$13.4M
4
BXLT
BAXALTA INC COM STK (DE)
BXLT
+$12.5M
5
ALR
Alere Inc
ALR
+$11.6M

Sector Composition

Rank Sector Weight
1 Healthcare 87.12%
2 Real Estate 4.77%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASRT
101
DELISTED
Assertio
ASRT
$2.79M 0.12%
3,333
– –
ORKA
102
Oruka Therapeutics
ORKA
$5.9B
$2.78M 0.12%
3,756
– –
CPXX
103
DELISTED
CELATOR PHARMACEUTICALS INC. COMMON STOCK
CPXX
$2.6M 0.11%
+236,000
New +$774K
GRFS
104
Grifois
GRFS
$5.58B
$2.57M 0.11%
166,000
– –
ADAP
105
DELISTED
Adaptimmune Therapeutics
ADAP
$2.41M 0.1%
296,934
– –
LXRX icon
106
Lexicon Pharmaceuticals
LXRX
$1.04B
$2.36M 0.1%
197,641
– –
DCOY
107
Decoy Therapeutics
DCOY
$2.09M
– –
0
– –
FWP
108
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$2.32M 0.1%
19,507
– –
MDRX
109
DELISTED
Veradigm Inc. Common Stock
MDRX
$2.29M 0.1%
173,600
– –
INSM icon
110
Insmed
INSM
$22B
$2.26M 0.1%
178,600
+22,000
+14% +$289K
CCP
111
DELISTED
Care Capital Properties, Inc.
CCP
$2.26M 0.1%
84,316
– –
FOLD
112
DELISTED
Amicus Therapeutics
FOLD
$2.18M 0.09%
+258,000
New +$1.83M
CYNA
113
DELISTED
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
$2.15M 0.09%
180,407
– –
DBVT
114
DBV Technologies
DBVT
$817M
$2.13M 0.09%
6,560
– –
BLUE
115
DELISTED
bluebird bio
BLUE
$2.1M 0.09%
3,809
– –
HALO icon
116
Halozyme
HALO
$9.88B
$1.89M 0.08%
200,000
– –
KITE
117
DELISTED
Kite Pharma, Inc.
KITE
$1.88M 0.08%
41,000
– –
NVAX icon
118
Novavax
NVAX
$1.22B
$1.85M 0.08%
17,900
– –
ESPR
119
DELISTED
Esperion Therapeutics
ESPR
$1.74M 0.07%
102,800
– –
CMRX
120
DELISTED
Chimerix, Inc.
CMRX
$1.58M 0.07%
308,892
+261,092
+546% +$1.7M
MNTA
121
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$1.42M 0.06%
153,700
– –
ADYX
122
DELISTED
Adynxx Inc
ADYX
$1.35M 0.06%
27,500
– –
AFMD
123
DELISTED
Affimed
AFMD
$1.1M 0.05%
29,421
– –
CDTX
124
DELISTED
Cidara Therapeutics
CDTX
$921K 0.04%
3,625
+1,000
+38% +$230K
TTPH
125
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$890K 0.04%
9,616
– –
2 3 4
5
6

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q1 2016 Portfolio in Review

As of Q1 2016, Tekla Capital Management held 145 positions worth $2.35B, down 15% from $2.76B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Tekla Capital Management's Q1 2016 filing shows 11 new, 25 increased, 9 reduced and 5 closed positions. Its largest new stake was Jazz Pharmaceuticals: 179,091 shares worth $23.4M. The largest sale was Johnson & Johnson, an estimated $58.6M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, down from 88% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q1 2016 buy was Jazz Pharmaceuticals: 179,091 shares worth $23.4M.
  • Tekla Capital Management added most to Medtronic in Q1 2016, an estimated $32.6M increase.
  • Tekla Capital Management's biggest Q1 2016 reduction was Johnson & Johnson, cutting an estimated $58.6M.
  • Tekla Capital Management fully exited BAXALTA INC COM STK (DE) in Q1 2016, selling an estimated $12.5M.
  • Tekla Capital Management's ten largest holdings make up 43% of its $2.35B portfolio in Q1 2016.
  • Tekla Capital Management opened 11 new positions and closed 5 in Q1 2016.
  • Tekla Capital Management's portfolio value fell 15% quarter-over-quarter to $2.35B.

Based on Tekla Capital Management's 13F filing for Q1 2016, filed 9 May 2016.